You are here

Electrophysiology & Arrhythmia


Major electrophysiology and cardiology societies released an expert consensus statement on Nov. 19 on optimal implantable cardioverter-defibrillator (ICD) programming and testing.


Recent Headlines

FDA approves app-based remote monitoring system for patients with implantable pacemakers

On Nov. 17, the FDA approved the MyCareLink Smart Monitor, the first app-based remote monitoring system in the U.S. for patients with implantable pacemakers.

AHA.15: Micra leadless pacemaker is safe and effective at 6 months

Six months after implantation with an investigational leadless intracardiac transcatheter pacing system from Medtronic, 96 percent of patients did not have system-related or procedure-related major complications, according to a prespecified interim analysis of a prospective, multicenter study.

The Beauty of Subcutaneous ICDs Is Not Merely Skin Deep

Wireless pacemakers today are rising in popularity as the right choice for many patients.

FDA approves first MRI-compatible ICD system

The FDA approved the Evera MRI Surescan implantable cardioverter defibrillator (ICD) as the first ICD system for use with MRI scans. The system is expected to be available this month.

Trial: St. Jude's cardiac leadless pacemaker is safe and effective at 6 months

After six months of nonsurgical implantation with an active-fixation leadless cardiac pacemaker, 90 percent of patients had an acceptable pacing threshold and sensing amplitude, according to a prespecified analysis of an ongoing study. In addition, 6.7 percent of patients had device-related serious adverse events.

ACC plans to launch two atrial fibrillation registries

The American College of Cardiology (ACC) announced it plans on launching two clinical registry programs to track outcomes in patients with atrial fibrillation. The registries will be part of the National Cardiovascular Data Registry, which currently includes eight cardiovascular data registries.

FDA warns of deaths, adverse events with the Lariat device

The FDA issued a safety alert on July 13, warning of deaths and severe adverse events associated with the use of SentreHEART's Lariat suture delivery device for left atrial appendage (LAA) exclusion and preventing strokes in patients with atrial fibrillation.

Study finds 7% malfunction rate in CIEDs attributable to radiotherapy

A retrospective analysis found 7 percent of patients with cardiovascular implantable electronic devices (CIEDs) had a malfunction attributed to radiotherapy. All of the cases occurred during neuron-producing radiotherapy, prompting lead researcher Jonathan D. Grant, MD, to recommend the use of non-neutron-producing radiotherapy when clinically feasible.

Fewer than 10% of Medicare beneficiaries receive an ICD after MI

Fewer than 10 percent of older adults received an implantable cardioverter-defibrillator (ICD) following an MI, according to an analysis of Medicare beneficiaries who had low ejection fraction. Although the patients were at an increased risk of sudden cardiac death, only 8.1 percent were implanted with the device within a year of their MI event.

No anticoagulation bridging for elective procedures offers benefits

Here’s a bridge you may consider burning: anticoagulation bridging therapy for patients with atrial fibrillation who undergo an elective operation. A randomized clinical trial found no bridging after discontinuing warfarin led to no more thromboembolic events than bridging, with a lower risk of bleeding.